Conversely, other studies report nuclear localization of PRMT5 to be associated with reduced cell growth and better patient outcomes in breast cancer and prostate cancer where nuclear exclusion signals have been identified [53–55]. This evidence concerns the gene PRMT5 and prostate carcinoma.